ArticleAdvances in virology2013
Influenza a virus entry: implications in virulence and future therapeutics.
Article in Advances in virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Avian lung single-cell atlas elucidates evolutionary divergence in endothermic respiration.Molecular biology and evolution · 2026Article
- Serological Evidence of Highly Pathogenic Avian Influenza (H5N1) in Invasive Wild Pigs in Western Canada.Transboundary and emerging diseases · 2025Article
- Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments.Chemical reviews · 2022Review
- Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases.Molecular aspects of medicine · 2021Review
- Deficiency of HIF-1α enhances influenza A virus replication by promoting autophagy in alveolar type II epithelial cells.Emerging microbes & infections · 2020Article
- Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance.Current medicinal chemistry · 2018Review
- Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase.Molecular therapy oncolytics · 2017Article
- Article
- Antiviral strategies against influenza virus: towards new therapeutic approaches.Cellular and molecular life sciences : CMLS · 2014Review
- Conformation and Linkage Studies of Specific Oligosaccharides Related to H1N1, H5N1, and Human Flu for Developing the Second Tamiflu.Biomolecules & therapeutics · 2014Review
- Cell cycle regulation during viral infection.Methods in molecular biology (Clifton, N.J.) · 2014Review
- Article
- The viruses of wild pigeon droppings.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza A viruses have broad host tropism, being able to infect a range of hosts from wild fowl to swine to humans. This broad tropism makes highly pathogenic influenza A strains, such as H5N1, potentially dangerous to humans if they gain the ability to jump from an animal reservoir to humans. How influenza A viruses are able to jump the species barrier is incompletely understood due to the complex genetic nature of the viral surface glycoprotein, hemagglutinin, which mediates entry, combined with the virus's ability to use various receptor linkages. Current therapeutics against influenza A include those that target the uncoating process after entry as well as those that prevent viral budding. While there are therapeutics in development that target entry, currently there are none clinically available. We review here the genetics of influenza A viruses that contribute to entry tropism, how these genetic alterations may contribute to receptor usage and species tropism, as well as how novel therapeutics can be developed that target the major surface glycoprotein, hemagglutinin.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.